Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 5712 entries
Sorted by: Best Match Show Resources per page
Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe.

Journal of market access & health policy

Medic G, Korchagina D, Young KE, Toumi M, Postma MJ, Wille M, Hemels M.
PMID: 28473888
J Mark Access Health Policy. 2017 Apr 10;5(1):1299665. doi: 10.1080/20016689.2017.1299665. eCollection 2017.

No abstract available.

Cite
Medic G, Korchagina D, Young KE, et al. Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe. J Mark Access Health Policy. 2017;5(1):1299665doi: 10.1080/20016689.2017.1299665.
Medic, G., Korchagina, D., Young, K. E., Toumi, M., Postma, M. J., Wille, M., & Hemels, M. (2017). Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe. Journal of market access & health policy, 5(1), 1299665. https://doi.org/10.1080/20016689.2017.1299665
Medic, Goran, et al. "Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe." Journal of market access & health policy vol. 5,1 (2017): 1299665. doi: https://doi.org/10.1080/20016689.2017.1299665
Medic G, Korchagina D, Young KE, Toumi M, Postma MJ, Wille M, Hemels M. Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe. J Mark Access Health Policy. 2017 Apr 10;5(1):1299665. doi: 10.1080/20016689.2017.1299665. eCollection 2017. PMID: 28473888; PMCID: PMC5405566.
Copy Download .nbib Format: NLM
New Product Development in the Pharmaceutical Industry: Evidence from a generic market.

Iranian journal of pharmaceutical research : IJPR

Yousefi N, Mehralian G, Rasekh HR, Yousefi M.
PMID: 28979339
Iran J Pharm Res. 2017;16(2):834-846.

In today's competitive world, there are several strategies to deal with the fast changing environment, among which New product development (NPD) is a common strategy. However, almost half of the resources that companies devote to NPD are spent on...

Cite
Yousefi N, Mehralian G, Rasekh HR, et al. New Product Development in the Pharmaceutical Industry: Evidence from a generic market. Iran J Pharm Res. 2017;16(2):834-846
Yousefi, N., Mehralian, G., Rasekh, H. R., & Yousefi, M. (2017). New Product Development in the Pharmaceutical Industry: Evidence from a generic market. Iranian journal of pharmaceutical research : IJPR, 16(2), 834-846.
Yousefi, Nazila, et al. "New Product Development in the Pharmaceutical Industry: Evidence from a generic market." Iranian journal of pharmaceutical research : IJPR vol. 16,2 (2017): 834-846.
Yousefi N, Mehralian G, Rasekh HR, Yousefi M. New Product Development in the Pharmaceutical Industry: Evidence from a generic market. Iran J Pharm Res. 2017;16(2):834-846. PMID: 28979339; PMCID: PMC5603895.
Copy Download .nbib Format: NLM
The Authors' Reply: Comment on "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy".

PharmacoEconomics

Grutters JP, van Asselt MB, Chalkidou K, Joore MA.
PMID: 26314283
Pharmacoeconomics. 2015 Sep;33(9):983. doi: 10.1007/s40273-015-0321-8.

No abstract available.

Cite
Grutters JP, van Asselt MB, Chalkidou K, et al. The Authors' Reply: Comment on "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy". Pharmacoeconomics. 2015;33(9):983doi: 10.1007/s40273-015-0321-8.
Grutters, J. P., van Asselt, M. B., Chalkidou, K., & Joore, M. A. (2015). The Authors' Reply: Comment on "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy". PharmacoEconomics, 33(9), 983. https://doi.org/10.1007/s40273-015-0321-8
Grutters, Janneke P C, et al. "The Authors' Reply: Comment on "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy"." PharmacoEconomics vol. 33,9 (2015): 983. doi: https://doi.org/10.1007/s40273-015-0321-8
Grutters JP, van Asselt MB, Chalkidou K, Joore MA. The Authors' Reply: Comment on "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy". Pharmacoeconomics. 2015 Sep;33(9):983. doi: 10.1007/s40273-015-0321-8. PMID: 26314283.
Copy Download .nbib Format: NLM
Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance.

Therapeutic advances in drug safety

Dore DD, Seeger JD, Chan KA.
PMID: 25083233
Ther Adv Drug Saf. 2012 Aug;3(4):157-64. doi: 10.1177/2042098612446473.

OBJECTIVES: As part of a regulatory postmarketing commitment, we assessed the risk of claims for thyroid and pancreatic cancer among users of exenatide using an active drug safety surveillance system.METHODS: This active surveillance assessment used cohort methodology and commercial...

Cite
Dore DD, Seeger JD, Chan KA. Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance. Ther Adv Drug Saf. 2012;3(4):157-64doi: 10.1177/2042098612446473.
Dore, D. D., Seeger, J. D., & Chan, K. A. (2012). Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance. Therapeutic advances in drug safety, 3(4), 157-64. https://doi.org/10.1177/2042098612446473
Dore, David D, et al. "Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance." Therapeutic advances in drug safety vol. 3,4 (2012): 157-64. doi: https://doi.org/10.1177/2042098612446473
Dore DD, Seeger JD, Chan KA. Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance. Ther Adv Drug Saf. 2012 Aug;3(4):157-64. doi: 10.1177/2042098612446473. PMID: 25083233; PMCID: PMC4110848.
Copy Download .nbib Format: NLM
A Systematic Review of Research Guidelines in Decision-Analytic Modeling.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Ramos MC, Barton P, Jowett S, Sutton AJ.
PMID: 26091606
Value Health. 2015 Jun;18(4):512-29. doi: 10.1016/j.jval.2014.12.014. Epub 2015 Feb 07.

BACKGROUND: Decision-analytic modeling (DAM) has been increasingly used to aid decision making in health care. The growing use of modeling in economic evaluations has led to increased scrutiny of the methods used.OBJECTIVE: The objective of this study was to...

Cite
Ramos MC, Barton P, Jowett S, et al. A Systematic Review of Research Guidelines in Decision-Analytic Modeling. Value Health. 2015;18(4):512-29doi: 10.1016/j.jval.2014.12.014.
Ramos, M. C., Barton, P., Jowett, S., & Sutton, A. J. (2015). A Systematic Review of Research Guidelines in Decision-Analytic Modeling. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 18(4), 512-29. https://doi.org/10.1016/j.jval.2014.12.014
Ramos, Maria Cristina Peñaloza, et al. "A Systematic Review of Research Guidelines in Decision-Analytic Modeling." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 18,4 (2015): 512-29. doi: https://doi.org/10.1016/j.jval.2014.12.014
Ramos MC, Barton P, Jowett S, Sutton AJ. A Systematic Review of Research Guidelines in Decision-Analytic Modeling. Value Health. 2015 Jun;18(4):512-29. doi: 10.1016/j.jval.2014.12.014. Epub 2015 Feb 07. PMID: 26091606.
Copy Download .nbib Format: NLM
A systematic review of prescription pattern monitoring studies and their effectiveness in promoting rational use of medicines.

Perspectives in clinical research

Jain S, Upadhyaya P, Goyal J, Kumar A, Jain P, Seth V, Moghe VV.
PMID: 25878953
Perspect Clin Res. 2015 Apr-Jun;6(2):86-90. doi: 10.4103/2229-3485.154005.

Prescription pattern monitoring studies (PPMS) are a tool for assessing the prescribing, dispensing and distribution of medicines. The main aim of PPMS is to facilitate rational use of medicines (RUM). There is paucity of published data analysing the effectiveness...

Cite
Jain S, Upadhyaya P, Goyal J, et al. A systematic review of prescription pattern monitoring studies and their effectiveness in promoting rational use of medicines. Perspect Clin Res. 2015;6(2):86-90doi: 10.4103/2229-3485.154005.
Jain, S., Upadhyaya, P., Goyal, J., Kumar, A., Jain, P., Seth, V., & Moghe, V. V. (2015). A systematic review of prescription pattern monitoring studies and their effectiveness in promoting rational use of medicines. Perspectives in clinical research, 6(2), 86-90. https://doi.org/10.4103/2229-3485.154005
Jain, Shipra, et al. "A systematic review of prescription pattern monitoring studies and their effectiveness in promoting rational use of medicines." Perspectives in clinical research vol. 6,2 (2015): 86-90. doi: https://doi.org/10.4103/2229-3485.154005
Jain S, Upadhyaya P, Goyal J, Kumar A, Jain P, Seth V, Moghe VV. A systematic review of prescription pattern monitoring studies and their effectiveness in promoting rational use of medicines. Perspect Clin Res. 2015 Apr-Jun;6(2):86-90. doi: 10.4103/2229-3485.154005. PMID: 25878953; PMCID: PMC4394586.
Copy Download .nbib Format: NLM
Advancing High-Quality Value Assessments of Health Care Interventions.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Doshi JA, Willke RJ.
PMID: 28237192
Value Health. 2017 Feb;20(2):181-184. doi: 10.1016/j.jval.2016.12.012. Epub 2017 Jan 27.

No abstract available.

Cite
Doshi JA, Willke RJ. Advancing High-Quality Value Assessments of Health Care Interventions. Value Health. 2017;20(2):181-184doi: 10.1016/j.jval.2016.12.012.
Doshi, J. A., & Willke, R. J. (2017). Advancing High-Quality Value Assessments of Health Care Interventions. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 20(2), 181-184. https://doi.org/10.1016/j.jval.2016.12.012
Doshi, Jalpa A, and Willke, Richard J. "Advancing High-Quality Value Assessments of Health Care Interventions." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 20,2 (2017): 181-184. doi: https://doi.org/10.1016/j.jval.2016.12.012
Doshi JA, Willke RJ. Advancing High-Quality Value Assessments of Health Care Interventions. Value Health. 2017 Feb;20(2):181-184. doi: 10.1016/j.jval.2016.12.012. Epub 2017 Jan 27. PMID: 28237192.
Copy Download .nbib Format: NLM
UTILISATION ANALYSIS OF ANTIHYPERTENSIVE DRUGS IN BOSNIA AND HERZEGOVINA FOR THE TIME-PERIOD 2013-2015.

Materia socio-medica

Selmanovic K, Zec SL, Vanis N, Zecevic L, Setkic M, Rasic A, Zerem E.
PMID: 27147917
Mater Sociomed. 2016 Apr;28(2):116-20. doi: 10.5455/msm.2016.28.116-120. Epub 2016 Mar 25.

OBJECTIVE: Expenditures for drugs are increasingly burdening already insufficient funds for health protection. This is especially evident in less developed European countries such as Bosnia and Herzegovina. The question is whether such analyses can help save funds for financing...

Cite
Selmanovic K, Zec SL, Vanis N, et al. UTILISATION ANALYSIS OF ANTIHYPERTENSIVE DRUGS IN BOSNIA AND HERZEGOVINA FOR THE TIME-PERIOD 2013-2015. Mater Sociomed. 2016;28(2):116-20doi: 10.5455/msm.2016.28.116-120.
Selmanovic, K., Zec, S. L., Vanis, N., Zecevic, L., Setkic, M., Rasic, A., & Zerem, E. (2016). UTILISATION ANALYSIS OF ANTIHYPERTENSIVE DRUGS IN BOSNIA AND HERZEGOVINA FOR THE TIME-PERIOD 2013-2015. Materia socio-medica, 28(2), 116-20. https://doi.org/10.5455/msm.2016.28.116-120
Selmanovic, Kenan, et al. "UTILISATION ANALYSIS OF ANTIHYPERTENSIVE DRUGS IN BOSNIA AND HERZEGOVINA FOR THE TIME-PERIOD 2013-2015." Materia socio-medica vol. 28,2 (2016): 116-20. doi: https://doi.org/10.5455/msm.2016.28.116-120
Selmanovic K, Zec SL, Vanis N, Zecevic L, Setkic M, Rasic A, Zerem E. UTILISATION ANALYSIS OF ANTIHYPERTENSIVE DRUGS IN BOSNIA AND HERZEGOVINA FOR THE TIME-PERIOD 2013-2015. Mater Sociomed. 2016 Apr;28(2):116-20. doi: 10.5455/msm.2016.28.116-120. Epub 2016 Mar 25. PMID: 27147917; PMCID: PMC4851497.
Copy Download .nbib Format: NLM
Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countries-Forecasts to 2020.

Frontiers in public health

Jakovljevic M, Malmose-Stapelfeldt C, Milovanovic O, Rancic N, Bokonjic D.
PMID: 28289676
Front Public Health. 2017 Feb 27;5:23. doi: 10.3389/fpubh.2017.00023. eCollection 2017.

BACKGROUND: Disability either due to illness, aging, or both causes remains an essential contributor shaping European labor markets. Ability of modern day welfare states to compensate an impaired work ability and absenteeism arising from incapacity is very diverse. The...

Cite
Jakovljevic M, Malmose-Stapelfeldt C, Milovanovic O, et al. Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countries-Forecasts to 2020. Front Public Health. 2017;5:23doi: 10.3389/fpubh.2017.00023.
Jakovljevic, M., Malmose-Stapelfeldt, C., Milovanovic, O., Rancic, N., & Bokonjic, D. (2017). Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countries-Forecasts to 2020. Frontiers in public health, 523. https://doi.org/10.3389/fpubh.2017.00023
Jakovljevic, Mihajlo, et al. "Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countries-Forecasts to 2020." Frontiers in public health vol. 5 (2017): 23. doi: https://doi.org/10.3389/fpubh.2017.00023
Jakovljevic M, Malmose-Stapelfeldt C, Milovanovic O, Rancic N, Bokonjic D. Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countries-Forecasts to 2020. Front Public Health. 2017 Feb 27;5:23. doi: 10.3389/fpubh.2017.00023. eCollection 2017. PMID: 28289676; PMCID: PMC5327442.
Copy Download .nbib Format: NLM
Insurance companies' point of view toward moral hazard incentives.

Journal of medical ethics and history of medicine

Khorasani E, Keyvanara M, Etemadi M, Asadi S, Mohammadi M, Barati M.
PMID: 28050242
J Med Ethics Hist Med. 2016 Nov 05;9:12. eCollection 2016.

Moral hazards are the result of an expansive range of factors mostly originating in the patients' roles. The objective of the present study was to investigate patient incentives for moral hazards using the experiences of experts of basic Iranian...

Cite
Khorasani E, Keyvanara M, Etemadi M, et al. Insurance companies' point of view toward moral hazard incentives. J Med Ethics Hist Med. 2016;9:12
Khorasani, E., Keyvanara, M., Etemadi, M., Asadi, S., Mohammadi, M., & Barati, M. (2016). Insurance companies' point of view toward moral hazard incentives. Journal of medical ethics and history of medicine, 912.
Khorasani, Elahe, et al. "Insurance companies' point of view toward moral hazard incentives." Journal of medical ethics and history of medicine vol. 9 (2016): 12.
Khorasani E, Keyvanara M, Etemadi M, Asadi S, Mohammadi M, Barati M. Insurance companies' point of view toward moral hazard incentives. J Med Ethics Hist Med. 2016 Nov 05;9:12. eCollection 2016. PMID: 28050242; PMCID: PMC5203681.
Copy Download .nbib Format: NLM
A Comparison of Inpatient Cost Per Day in General Surgery Patients with Type 2 Diabetes Treated with Basal-Bolus versus Sliding Scale Insulin Regimens.

PharmacoEconomics - open

Phillips VL, Byrd AL, Adeel S, Peng L, Smiley DD, Umpierrez GE.
PMID: 28660256
Pharmacoecon Open. 2017;1(2):109-115. doi: 10.1007/s41669-017-0020-9. Epub 2017 Apr 21.

BACKGROUND: The identification of cost-effective glycaemic management strategies is critical to hospitals. Treatment with a basal-bolus insulin (BBI) regimen has been shown to result in better glycaemic control and fewer complications than sliding scale regular insulin (SSI) in general...

Cite
Phillips VL, Byrd AL, Adeel S, et al. A Comparison of Inpatient Cost Per Day in General Surgery Patients with Type 2 Diabetes Treated with Basal-Bolus versus Sliding Scale Insulin Regimens. Pharmacoecon Open. 2017;1(2):109-115doi: 10.1007/s41669-017-0020-9.
Phillips, V. L., Byrd, A. L., Adeel, S., Peng, L., Smiley, D. D., & Umpierrez, G. E. (2017). A Comparison of Inpatient Cost Per Day in General Surgery Patients with Type 2 Diabetes Treated with Basal-Bolus versus Sliding Scale Insulin Regimens. PharmacoEconomics - open, 1(2), 109-115. https://doi.org/10.1007/s41669-017-0020-9
Phillips, Victoria L, et al. "A Comparison of Inpatient Cost Per Day in General Surgery Patients with Type 2 Diabetes Treated with Basal-Bolus versus Sliding Scale Insulin Regimens." PharmacoEconomics - open vol. 1,2 (2017): 109-115. doi: https://doi.org/10.1007/s41669-017-0020-9
Phillips VL, Byrd AL, Adeel S, Peng L, Smiley DD, Umpierrez GE. A Comparison of Inpatient Cost Per Day in General Surgery Patients with Type 2 Diabetes Treated with Basal-Bolus versus Sliding Scale Insulin Regimens. Pharmacoecon Open. 2017;1(2):109-115. doi: 10.1007/s41669-017-0020-9. Epub 2017 Apr 21. PMID: 28660256; PMCID: PMC5468101.
Copy Download .nbib Format: NLM
Improvement in Long-Term Memory following Chronic Administration of Eryngium planum Root Extract in Scopolamine Model: Behavioral and Molecular Study.

Evidence-based complementary and alternative medicine : eCAM

Ozarowski M, Thiem B, Mikolajczak PL, Piasecka A, Kachlicki P, Szulc M, Kaminska E, Bogacz A, Kujawski R, Bartkowiak-Wieczorek J, Kujawska M, Jodynis-Liebert J, Budzianowski J, Kędziora I, Seremak-Mrozikiewicz A, Czerny B, Bobkiewicz-Kozłowska T.
PMID: 26483842
Evid Based Complement Alternat Med. 2015;2015:145140. doi: 10.1155/2015/145140. Epub 2015 Sep 21.

Eryngium planum L. (EP) is as a rare medicinal plant with a lot of potentials as pharmaceutical crops. The aim of our study was to assess the effect of subchronic (28-fold) administration of a 70% ethanol extract of EP...

Cite
Ozarowski M, Thiem B, Mikolajczak PL, et al. Improvement in Long-Term Memory following Chronic Administration of Eryngium planum Root Extract in Scopolamine Model: Behavioral and Molecular Study. Evid Based Complement Alternat Med. 2015;2015:145140doi: 10.1155/2015/145140.
Ozarowski, M., Thiem, B., Mikolajczak, P. L., Piasecka, A., Kachlicki, P., Szulc, M., Kaminska, E., Bogacz, A., Kujawski, R., Bartkowiak-Wieczorek, J., Kujawska, M., Jodynis-Liebert, J., Budzianowski, J., Kędziora, I., Seremak-Mrozikiewicz, A., Czerny, B., & Bobkiewicz-Kozłowska, T. (2015). Improvement in Long-Term Memory following Chronic Administration of Eryngium planum Root Extract in Scopolamine Model: Behavioral and Molecular Study. Evidence-based complementary and alternative medicine : eCAM, 2015145140. https://doi.org/10.1155/2015/145140
Ozarowski, Marcin, et al. "Improvement in Long-Term Memory following Chronic Administration of Eryngium planum Root Extract in Scopolamine Model: Behavioral and Molecular Study." Evidence-based complementary and alternative medicine : eCAM vol. 2015 (2015): 145140. doi: https://doi.org/10.1155/2015/145140
Ozarowski M, Thiem B, Mikolajczak PL, Piasecka A, Kachlicki P, Szulc M, Kaminska E, Bogacz A, Kujawski R, Bartkowiak-Wieczorek J, Kujawska M, Jodynis-Liebert J, Budzianowski J, Kędziora I, Seremak-Mrozikiewicz A, Czerny B, Bobkiewicz-Kozłowska T. Improvement in Long-Term Memory following Chronic Administration of Eryngium planum Root Extract in Scopolamine Model: Behavioral and Molecular Study. Evid Based Complement Alternat Med. 2015;2015:145140. doi: 10.1155/2015/145140. Epub 2015 Sep 21. PMID: 26483842; PMCID: PMC4592897.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 5712 entries